Innovative Health Sciences (IHS) proudly announces a remarkable milestone in its journey to introduce the Insignis™ Infusion ...

Innovative Health Sciences has successfully secured the exclusive Medical Device Regulations Quality Management System Certificate from BSI (CE MDR QMS), a leading notified body, thus facilitating ...

Analysts have recently evaluated KORU Medical Systems and provided 12-month price targets. The average target is $4.7, ...

If LEQEMBI subcutaneous maintenance dosing is approved by the FDA ... 46 70 410 71 80 About lecanemab (Leqembi ®) Lecanemab is the result of a strategic research alliance between BioArctic and Eisai.

BioArctic announces US FDA accepts Eisai’s BLA for subcutaneous maintenance dosing of Leqembi: Stockholm Wednesday, January 15, 2025, 13:00 Hrs [IST] BioArctic AB (publ) announc ...

Mirikizumab is a humanized immunoglobulin G4 monoclonal antibody that selectively binds to the p19 subunit of human interleukin (IL)-23.

Preliminary U.S. BRIUMVI fourth quarter and full year 2024 net product revenue of $103.6 million and $310 million, respectivelyFull Year 2025 ...

Researchers uncover how influenza A virus infects dairy cattle, revealing the mammary gland's surprising role in viral ...

Adding a PD-1 antibody to BCG led to improved event-free survival in patients with non–muscle invasive bladder cancer.

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.